GlassScriptPhysician profile
Manijeh E Lani
NPI 1023263340
$1,382.71
in general payments reported to CMS, 2019-2025
16 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,059 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $197.75 | 2024-2025 | |
| Sk Life Science, INC. | $152.95 | 2024-2025 | |
| Amgen INC. | $139.25 | 2024 | Evenity |
| Lilly USA, LLC | $133.23 | 2024-2025 | Amyvid, Emgality, Kisunla |
| Acadia Pharmaceuticals INC | $121.43 | 2024-2025 | Nuplazid |
| Lundbeck LLC | $116.89 | 2024-2025 | Vyepti, Rexulti |
| Mdd US Operations, LLC | $98.09 | 2024 | Gocovri |
| Teva Pharmaceuticals USA, INC. | $77.81 | 2024 | Austedo Xr, Ajovy |
| Otter Pharmaceuticals, LLC | $73.94 | 2024-2025 | Sympazan |
| Jazz Pharmaceuticals INC. | $66.85 | 2024 | |
| Biogen, INC. | $64.69 | 2024-2025 | Leqembi, Vumerity, Tysabri |
| Kyowa Kirin, INC. | $45.87 | 2024 | Nourianz |
| Azurity Pharmaceuticals, INC. | $31.80 | 2024 | Horizant |
| Harmony Biosciences LLC | $28.47 | 2024 | |
| Eisai INC. | $18.69 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manijeh Lani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.